S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:ABUS

Arbutus Biopharma News Headlines

$2.68
-0.13 (-4.63%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.63
$2.86
50-Day Range
$2.68
$4.61
52-Week Range
$2.43
$6.50
Volume
5.30 million shs
Average Volume
3.01 million shs
Market Capitalization
$362.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.66
Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Arbutus Biopharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ABUS
News Sentiment

0.28

0.40

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ABUS Articles
This Week

4

1

ABUS Articles
Average Week



Arbutus Biopharma (NASDAQ:ABUS) News Headlines Today

SourceHeadline
finance.yahoo.com logoArbutus to Participate at H.C. Wainwright Bioconnect Virtual Conference
finance.yahoo.com - January 4 at 11:12 AM
finance.yahoo.com logoAntios Therapeutics and Arbutus Biopharma Announce First Patient Dosed in Phase 2a Combination Trial of ATI-2173, AB-729 and Tenofovir Disoproxil Fumarate in Patients with Chronic Hepatitis B Virus Infection
finance.yahoo.com - December 14 at 12:57 PM
nasdaq.com logoArbutus, Qilu To Develop, Commercialize AB-729 In Mainland China, Hong Kong, Macau And Taiwan
nasdaq.com - December 13 at 11:54 AM
markets.businessinsider.com logoWhy Arbutus Biopharma Shares Are Rising
markets.businessinsider.com - December 13 at 11:54 AM
finance.yahoo.com logoArbutus and Qilu Pharmaceutical Enter into an Exclusive Licensing Agreement and Strategic Partnership to Develop and Commercialize AB-729 in mainland China, Hong Kong, Macau and Taiwan
finance.yahoo.com - December 13 at 11:54 AM
finance.yahoo.com logoArbutus enters into $300M deal for experimental hepatitis B drug with Chinese pharma firm
finance.yahoo.com - December 13 at 11:54 AM
bizjournals.com logoLab Notes: Arbutus and Penn make headway on Covid-19 treatments; Carisma partners with Merck
bizjournals.com - December 10 at 1:49 PM
nasdaq.com logoKeep on Buying Arbutus Stock Before It Jumps 80%, Says Analyst
nasdaq.com - December 9 at 5:16 PM
finance.yahoo.com logoKeep on Buying Arbutus Stock Before It Jumps 80%, Says Analyst
finance.yahoo.com - December 9 at 5:16 PM
markets.businessinsider.com logoArbutus Biopharma Shares Jump After Achieving First Milestone Under COVID-19 Pact
markets.businessinsider.com - December 7 at 12:52 PM
finance.yahoo.com logoArbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement
finance.yahoo.com - December 7 at 7:52 AM
msn.com logoArbutus Shares Rise Moderna's Fall After Patent Appeal Denied
msn.com - December 2 at 8:08 PM
finance.yahoo.com logoArbutus: Still Plenty of Upside Left Following Favorable Court Decision
finance.yahoo.com - December 2 at 3:07 PM
finance.yahoo.com logoPreliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
finance.yahoo.com - December 1 at 1:35 PM
finance.yahoo.com logoWhy Arbutus Biopharma Is Rocketing Higher Today
finance.yahoo.com - December 1 at 1:35 PM
finance.yahoo.com logoArbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors
finance.yahoo.com - November 11 at 7:37 AM
finance.yahoo.com logoArbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®
finance.yahoo.com - November 10 at 8:39 PM
finance.yahoo.com logoArbutus to Participate at Jefferies London Healthcare Conference
finance.yahoo.com - November 10 at 10:38 AM
finance.yahoo.com logoArbutus Biopharma (ABUS) Q3 2021 Earnings Call Transcript
finance.yahoo.com - November 5 at 1:23 AM
msn.com logoArbutus Biopharma (ABUS) Reports Q3 Loss, Tops Revenue Estimates
msn.com - November 4 at 10:17 AM
finance.yahoo.com logoArbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - November 4 at 10:17 AM
finance.yahoo.com logoArbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
finance.yahoo.com - October 21 at 9:49 AM
finance.yahoo.com logoArbutus Biopharma (NASDAQ:ABUS) shareholders have earned a 7.3% CAGR over the last five years
finance.yahoo.com - October 13 at 9:26 AM
nasdaq.com logoWhat Kind Of Investors Own Most Of Arbutus Biopharma Corporation (NASDAQ:ABUS)?
nasdaq.com - October 3 at 10:24 AM
finance.yahoo.com logoArbutus to Participate in October Investor Conferences
finance.yahoo.com - September 28 at 9:16 AM
finance.yahoo.com logoArbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
finance.yahoo.com - September 21 at 10:08 AM
finance.yahoo.com logoIs the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?
finance.yahoo.com - August 23 at 3:49 PM
finance.yahoo.com logoArbutus Biopharma (ABUS) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 7 at 11:15 AM
finance.yahoo.com logoArbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
finance.yahoo.com - August 5 at 3:08 PM
finance.yahoo.com logoArbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update
finance.yahoo.com - August 5 at 10:08 AM
nasdaq.com logoArbutus Biopharma Corporation Common Stock (ABUS)
nasdaq.com - July 30 at 11:06 PM
finance.yahoo.com logoArbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update
finance.yahoo.com - July 29 at 12:57 PM
theglobeandmail.com logoArbutus Biopharma Cp (ABUS-Q) Quote - Press Release - The Globe and Mail
theglobeandmail.com - July 15 at 6:34 PM
finance.yahoo.com logoArbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
finance.yahoo.com - July 7 at 8:46 AM
markets.businessinsider.com logoBullish Arbutus Biopharma Analyst Breaks Down Pipeline Opportunity
markets.businessinsider.com - July 6 at 7:21 PM
finance.yahoo.com logoArbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection
finance.yahoo.com - June 29 at 9:32 AM
baystreet.ca logoArbutus Climbs on New Data
baystreet.ca - June 28 at 1:34 PM
finance.yahoo.com logoArbutus Higher After Report of Progress With Hepatitis B Drug
finance.yahoo.com - June 28 at 1:34 PM
finance.yahoo.com logoPremarket Movers Monday: Intellia Therapeutics, Boeing, Nvidia
finance.yahoo.com - June 28 at 1:34 PM
finance.yahoo.com logoArbutus Biopharma Stock Jumps On Encouraging Data From Hepatitis B Candidate
finance.yahoo.com - June 28 at 1:34 PM
finance.yahoo.com logoHere's Why We're Not Too Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation
finance.yahoo.com - June 15 at 11:05 AM
finance.yahoo.com logoArbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June
finance.yahoo.com - June 2 at 12:19 PM
finance.yahoo.com logoArbutus to Participate in Upcoming Investor Conferences
finance.yahoo.com - May 26 at 8:12 AM
seekingalpha.com logoArbutus Biopharma Corporation (ABUS) CEO Bill Collier on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 7 at 3:05 PM
msn.com logoWhy Arbutus Biopharma's Stock Is Trading Lower Today
msn.com - May 5 at 5:06 PM
markets.businessinsider.com logoArbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
markets.businessinsider.com - May 5 at 12:06 PM
finance.yahoo.com logoArbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update
finance.yahoo.com - April 28 at 10:27 AM
finance.yahoo.com logoIntroducing Arbutus Biopharma (NASDAQ:ABUS), The Stock That Zoomed 167% In The Last Year
finance.yahoo.com - April 16 at 9:01 AM
au.finance.yahoo.com logoABUS Apr 2021 7.500 call
au.finance.yahoo.com - March 22 at 9:15 PM
finance.yahoo.com logoArbutus Gets Go Ahead To Kick Off Phase 1a/1b Clinical Trial Of AB-836
finance.yahoo.com - March 17 at 12:46 PM
Get Arbutus Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.